Pfizer, Chinese Biotech Firm 3SBio Complete Licensing Deal for Cancer Drug

Chinese firm seals largest biotech deal for cancer drug with Pfizer

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in mainland - Anadolu Ajansı

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.

Pfizer and 3SBio conclude licensing deal for SSGJ-707

Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the 3SBio’s SSGJ-707.

Pfizer completes licensing agreement with 3SBio - Express Pharma

Pfizer announced the completion of a global, ex-China, licensing agreement with 3SBio, granting Pfizer exclusive rights for the development, manufacturing and commercialisation of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio’s proprietary CLF2 platform.  SSGJ-707 is currently undergoing several clinical trials in China for non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynaecologica…